Sutro Biopharma’s Promising Market Expansion and Financial …

Nov 14, 2024 · Moreover, Sutro’s robust cash reserves of $388.3 million and partnerships offering non-dilutive capital further reinforce its financial stability and potential for growth.

$388
OFF

Sutro Biopharma’s Promising Market Expansion And Financial …

2 weeks from now

Nov 14, 2024 · Moreover, Sutro’s robust cash reserves of $388.3 million and partnerships offering non-dilutive capital further reinforce its financial stability and potential for growth.

businessinsider.com

$388
OFF

Strong Buy Rating For Sutro Biopharma Amid Promising

2 weeks from now

Dec 11, 2024 · Moreover, Sutro Biopharma benefits from a robust financial position, bolstered by non-dilutive capital partnerships and a healthy cash reserve of $388.3 million.

businessinsider.com

$388
OFF

Sutro Biopharma's SWOT Analysis: Promising Pipeline Drives Stock ...

2 weeks from now

Dec 15, 2024 · Sutro's financial position remains robust, with a cash balance of $388.3 million as of the end of Q3 2024. This strong cash position was bolstered by the sale of all Vaxcyte …

investing.com

76%
OFF

Peeling Back The Layers: Exploring Sutro Biopharma Through

2 weeks from now

Oct 11, 2024 · With a remarkable ROA of -10.76%, the company showcases efficient use of assets and strong financial health. Debt Management: Sutro Biopharma's debt-to-equity ratio …

nasdaq.com

FAQs about Sutro Biopharma’s Promising Market Expansion and Financial … Coupon?

Should you buy Sutro Biopharma (Stro – research report)?

JMP Securities analyst Reni Benjamin reiterated a Buy rating on Sutro Biopharma (STRO – Research Report) today and set a price target of $17.00. Reni Benjamin has given his Buy rating due to a combination of factors that highlight Sutro Biopharma’s promising prospects. ...

Who is Sutro Biopharma?

Begin your TipRanks Premium journey today. Sutro Biopharma (STRO) Company Description: Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. ...

Why did Reni Benjamin buy Sutro Biopharma?

Reni Benjamin has given his Buy rating due to a combination of factors that highlight Sutro Biopharma’s promising prospects. The company has demonstrated progress through its strategic expansion of luvelta into the NSCLC space, which signifies its potential to capture a broader market. ...

How much money does Sutro have in 2024?

As of June 30, 2024, Sutro had $426.0 million, composed of cash, cash equivalents and marketable securities of $375.6 million and approximately 0.7 million shares of Vaxcyte common stock with a fair value of $50.4 million - Recent Business Highlights and Select Anticipated Milestones Luveltamab Tazevibulin (luvelta), FRα-Targeting ADC Franchise: ...

How did Sutro strengthen its cash position?

Additionally, Sutro strengthened its cash position with an underwritten offering of 14,478,764 shares of its common stock at a price of $5.18 per share, resulting in gross proceeds of $75.0 million. The offering was led by a high-quality group of new and existing healthcare-focused institutional investors. ...

How did Sutro perform in the first quarter of 2024?

“The Sutro team executed on multiple fronts in the first quarter of 2024, advancing luvelta through the clinic in multiple indications of high unmet need, continuing to progress our pipeline and collaboration programs, and establishing a new licensing relationship with Ipsen. ...